longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

BIOKIN PHARMACEUTICAL

688506

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -64.20, within the reasonable range, cheaper than 44.96% of the time in the past 3 years, and the industry ranks 209/221, the industry Median 23.07.

-64.2xP/E
¥244.58Stock price
¥-3.81Earnings per share
-64.2xP/E
Stock price¥244.58Earnings per share¥-3.81

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-66.03x
Typical range
-97.75x–17.98x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 23.07x
019385776

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 23.07x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
688506SHBIOKIN PHARMACEUTICAL
-64.20x15.13%¥100.98B
000661SZCCHT
-83.69x588.46%¥29.51B
300255SZCSBIO
-60.90x--¥21.05B
300436SZCosunter
-65.15x--¥14.29B
300363SZPorton
-77.42x105.56%¥11.99B
000908SZCSPC Jingfeng
-252.41x--¥10.72B
301263SZT&K
-2,094.52x--¥9.91B
002099SZHISOAR
-51.66x--¥8.74B
688505SHFudan-Zhangjiang
-62.64x--¥7.91B
688176SHAsieris
-14.41x8.11%¥7.10B
600252SHZhongheng Group
-16.30x--¥7.04B
000813SZDEZHAN HEALTHCARE
-18.66x--¥6.73B
300267SZER-KANG
-17.64x--¥6.58B
002737SZSFPM
-25.23x--¥6.55B
002424SZGZBL
-48.98x--¥6.18B
600422SHKPC
-28.91x53.62%¥6.14B
000566SZHAINAN HAIYAO
-12.31x--¥5.95B
002082SZWBDE
-49.85x--¥5.85B
688658SHYKYY
-21.07x--¥5.66B
300006SZLummy
-43.07x--¥5.46B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.